Most early digital health founders think they need a name-brand health system logo before their proof content is worth publishing. They don't. What they have is usage data, and usage data tells a story investors already know how to read, if you write it as a story instead of a screenshot.
This matters most right before a raise, when the pressure to manufacture a case study is highest and the actual case study doesn't exist yet. The founders who handle that gap well don't invent one. They write honestly about the data they already have.
The reference trap
Ask a seed-stage founder for proof and they'll usually reach for the same three things: a testimonial from a pilot site, a logo they're not fully cleared to use, and a promise that a case study is "in progress."
None of that is wrong. It's just early. A single reference from one clinic or one health system carries less weight than founders think, especially pre-Series A. One reference is an anecdote. Investors know it. A sophisticated one will ask what happens across your other ten accounts before they trust the one glowing quote.
Treating that single reference as the whole proof is the real risk, not having only one. A founder who leads a pitch with one enthusiastic customer and nothing else invites the obvious question: what about the other nine.
What you actually have
By the time most digital health founders are fundraising, they're sitting on more proof than they think. Cohort retention curves. Time-to-first-value. Weekly active clinician counts against total licensed seats. Referral loops inside a practice, one provider telling another to try it.
None of that needs a customer's permission to publish. It's your data, aggregated and anonymized. And it answers the question investors actually care about at seed and Series A: not whether the product works, but whether usage compounds or decays.
That's the number that matters. A flat DAU line sitting under a big top-of-funnel number is a red flag dressed as a green one. A small cohort with retention that holds past week 8 is the opposite: unglamorous, and exactly what a health tech investor wants to see before they'll take a second meeting.
Founders often sit on this data without recognizing it as proof, because it doesn't feel like a result. A quote from a nurse practitioner feels like proof. A cohort curve in a spreadsheet doesn't, until someone writes down what it means.
Two kinds of usage data, and they're not interchangeable
Adoption data answers "will they start." Signups and completed first sessions. This is the easiest data to gather and the least persuasive. Every product looks good on day one, including the ones that get abandoned by week three.
Retention data answers "will they stay." Week 4 and week 12 cohort curves, and whether usage per account grows or shrinks over time. This is harder to gather cleanly, and it's the data that actually changes an investor's mind.
If you only have adoption numbers, say so, and be specific about when the retention picture will exist. Don't blur the two together to make an early number look more mature than it is. Investors in this category see a lot of decks. They notice when adoption is standing in for retention, and once they notice it once, they check every other number in the deck twice.
Building proof content around numbers you can defend
The instinct is to drop a chart into a blog post and call it proof. A chart dropped into a blog post is a slide caption. Proof content does three things a chart alone can't: it names the number, explains what changed the number, and states what it predicts.
Take a retention curve. Instead of publishing the chart with a caption like "our retention," write the piece around the decision that produced the curve. What did you change in week 6 that made week 12 retention hold instead of drop. What did clinicians tell you when usage dipped, and what did you build in response. The chart becomes evidence inside an argument, not the argument itself.
Say your week 4 retention sits at 58% and week 12 holds at 51%. On its own, that's two numbers. Written up properly, it's a story: what you assumed going in, what the data showed instead, the one workflow change that stopped the week 6 to week 8 drop-off, and what you're testing next to push week 12 higher. That version gets forwarded inside a fund. The chart alone gets glanced at and closed.
This matters more in health tech than most categories, because your reader is often a clinician-investor or a partner who's diligenced fifteen other digital health companies this quarter. They can spot a vanity metric from the subject line.
What this looks like as actual content
Two formats work better than a static "traction" page.
The build note. A short piece written the week you see a real inflection in a cohort curve, written as a working note: here's what the data showed, here's what we think it means, here's what we're testing next. This reads as live, which is exactly the credibility a case study can't offer yet. A build note published in March, before you're raising in September, does more work than the same content rewritten as a pitch deck slide the week you need it.
The investor update, made public. Founders already write these monthly. Strip the confidential numbers (burn, cap table) and the rest is often publishable as-is. It's proof that was never written to be proof, which is a big part of why it works. Fold in a short section on how you think about retention in your category specifically, not generically. Digital health retention curves don't behave like consumer app curves, and a founder who can explain why, with their own numbers, is doing due diligence for the investor before the investor asks for it.
Both formats share the same discipline: one honest number, one clear explanation, one specific next step. Skip the second and third and you're back to a slide caption.
Who actually reads this
Write for the associate who's building the diligence memo, not the partner who skims the deck. Associates read your public content before the first meeting happens, looking for a pattern: does this founder publish honestly when things are still uneven, or only when the number finally looks good.
A build note from four months ago showing a metric that dipped, and what you did about it, tells that associate more than a polished number published the week of your first call. The dip, explained well, reads as competence. The dip, hidden, reads as a founder who only shows up when the news is good, and that's the pattern every investor has learned to discount.
A quick gut check before you publish
Run any usage-data piece through four questions before it goes live: can you produce the raw number on request, does the cohort size appear next to the percentage, does the piece say what you don't know yet, and would the number survive being read by your toughest board member out loud.
If a draft fails any of those, it's not ready. Fix the number or fix the claim, not the phrasing around it. A vaguer sentence around a shaky number doesn't make the number safer, it just makes the piece harder to trust when someone eventually checks.
The line you don't cross
Every founder is tempted to round a number up once. Don't. A retention curve you can defend in diligence is worth more than one that looks better in the pitch deck and falls apart under a data room request.
If a number isn't clean yet, mark it as directional and say why. "Early cohort, n=40, holding through week 6" is more credible than a polished percentage with no denominator. Investors trust founders who show their methodology more than founders who show their best slide.
This is also where PulseCopy draws a hard line with clients. We won't write a number we can't trace back to a source the founder can produce on request. A directional number with an honest caveat survives diligence. An invented one doesn't, and it costs more than the deal it was meant to help close.
Where this fits your fundraising timeline
Content like this works best published before you're actively raising, not during. A retention explainer that's been live for four months and picked up a few inbound replies from operators in the space does more for a raise than the same piece dropped into a data room the week term sheets go out.
That's what proof content does when you don't have case studies yet. It's a record that traction existed before you needed it to prove itself.
Start with the number that's already true
You don't need a marquee customer to start publishing proof. You need one number you can defend, and one honest sentence about what you don't know yet. That's more persuasive to a health tech investor than a logo wall, and it's something you can write this week.